AHOLEA: Additional Hyperbaric Oxygen After Lower Extremity Amputation

Sponsor
Oslo University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03594344
Collaborator
Diakonhjemmet Hospital (Other)
120
2
2
65.9
60
0.9

Study Details

Study Description

Brief Summary

This study evaluates the effect of additional hyperbaric oxygen therapy after lower extremity amputation. The patients will be randomized after amputation to either a treatment group receiving hyperbaric oxygen therapy, or control group.

Detailed Description

Hyperbaric oxygen therapy has been used to treat hard to heal wounds for decades. Amputation, especially distal lower extremity amputations have the same problem with healing and patients often need to be re-amputated more proximally. In these patients oxygen levels are often the decisive factor. Providing additional oxygen under hyperbaric conditions will increase tissue oxygen concentration sufficient for the amputation stump to heal. This will give the patients a more distal amputation with better condition for ambulation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Additional Hyperbaric Oxygen After Lower Extremity Amputation - A Randomized Controlled Trial
Actual Study Start Date :
Jul 4, 2018
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Hyperbaric oxygen therapy

30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.

Procedure: Hyperbaric oxygen therapy
Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions

No Intervention: Control group

Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.

Outcome Measures

Primary Outcome Measures

  1. Intact skin with no abnormal openings at the site of primary amputation [12 weeks]

    Healed and intact skin at the site of primary amputation without need for more proximal amputation.Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon. Level of primary amputation is decided by the surgeon. Planned 2-session amputation, for example Guillotine amputation with a final amputation later is considered being primary amputation. Healed primary amputation will be measured at 12 weeks.

Secondary Outcome Measures

  1. Intact skin with no abnormal openings at the site of amputation at 6 months [6 months]

    Healed and intact skin at the site of amputation at follow up 6 months. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

  2. Intact skin with no abnormal openings at the site of amputation at 9 months [9 months]

    Healed and intact skin at the site of amputation at follow up 9 months. Will be assessed if the wound has not healed at 6 months. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

  3. Intact skin with no abnormal openings at the site of amputation at 1 year [12 months]

    Healed and intact skin at the site of amputation at follow up at 1 year. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

  4. Time to closed and intact skin at the site of amputation [1 year]

    Time to closed and intact skin at the site of amputation is the defined as how many weeks until complete healing of amputation. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon and no abnormal openings.

  5. Reamputations [1 year]

    The total number of reamputations done within the follow-up period of 1 year.

  6. Number of wound revision [1 year]

    The total numbers of surgical wound revision done in operating theater.

  7. Days in hospital during follow up [1 year]

    Total number of days in hospital during 1 year follow up

  8. Visual analog pain scale (VAS) [baseline]

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

  9. Visual analog pain scale (VAS) [12 weeks]

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

  10. Visual analog pain scale (VAS) [6 months]

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

  11. Visual analog pain scale (VAS) [1 year]

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

  12. RAND 36-Item Short Form Health Survey [baseline]

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

  13. RAND 36-Item Short Form Health Survey [12 weeks]

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

  14. RAND 36-Item Short Form Health Survey [6 months]

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

  15. RAND 36-Item Short Form Health Survey [1 year]

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

  16. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form [baseline]

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

  17. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form [12 weeks]

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

  18. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form [6 months]

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

  19. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form [1 year]

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

  20. The Foot and Ankle Ability Measure (FAAM) [baseline]

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

  21. The Foot and Ankle Ability Measure (FAAM) [12 weeks]

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

  22. The Foot and Ankle Ability Measure (FAAM) [6 months]

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

  23. The Foot and Ankle Ability Measure (FAAM) [1 year]

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Lower extremity amputation because of chronic wound, osteomyelitis, ischemia, necrosis.

  • Fit to receive hyperbaric oxygen therapy determined by an anesthesiologist/Hyperbaric Medicine Physician.

  • Able to cooperate and follow up appointments

  • Included within 7 days after final surgery

Exclusion Criteria:
  • Not fulfilling inclusion criteria

  • Pregnancy

  • Dementia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Diakonhjemmet Hospital Oslo Norway 0319
2 Orthopedic Center, Ullevål University Hopspital Oslo Norway 0407

Sponsors and Collaborators

  • Oslo University Hospital
  • Diakonhjemmet Hospital

Investigators

  • Principal Investigator: Jonas Thomassen, MD, Ullevål University Hospital, orthopedic department

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Elisabeth Ellingsen Husebye, Principal Investigator, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT03594344
Other Study ID Numbers:
  • 2017/1587
First Posted:
Jul 20, 2018
Last Update Posted:
Mar 4, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Elisabeth Ellingsen Husebye, Principal Investigator, Oslo University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 4, 2021